What is the 13F Pro Quality Score for VALN?

13F Pro ranks Valneva SE (VALN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VALN's current score at https://13fpro.ai/company/VALN (free sign-up required for the full ranking).

Where does 13F Pro source VALN data?

All Valneva SE fundamentals and ownership data come directly from SEC EDGAR. Valneva SE files with the SEC under CIK 1836564. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VALN in?

Valneva SE (VALN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VALN research updated on 13F Pro?

VALN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Valneva SE(VALN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1836564 VALN stock profile & AI dashboard →

13F Pro Quality Score

28.3/100

Rank #2,559 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

48.8/100

Profitability

8.9/100

Balance Sheet

9.6/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

10.3/100

Revenue Scale

21.9/100

Dilution Risk

94.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why VALN Scores 28/100

exact factor attribution · 2026-09-11

VALN's composite is driven by shareholder dilution, held back by profitability and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Shareholder dilution

+2.2 pts

95th pct

Revenue growth

-0.2 pts

49th pct

Institutional flow

-2.0 pts

10th pct

Earnings quality

-2.0 pts

30th pct

Earnings growth

-2.3 pts

4th pct

Free cash flow

-3.0 pts

30th pct

Capital efficiency

-4.0 pts

10th pct

Scale

-4.2 pts

22th pct

Profitability

-6.2 pts

9th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

VALN Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Valneva SE (VALN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VALN at 28.3/100 on a 32-signal composite quality model, placing it at rank #2,559 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (8.9) and balance sheet strength (9.6), which score below median versus the broader universe. Top institutional holders of VALN by reported 13-F value include Frazier Life Sciences Management, L.P., Vivo Capital, GENERAL AMERICAN INVESTORS, based on the most recent SEC filings. VALN trades on the Nasdaq exchange and files with the SEC under CIK 1836564. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VALN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Valneva SE directly from SEC EDGAR. Valneva SE's 13F Pro composite quality score has ranged between 28 and 33 since 2026, currently 28.3 — a declining long-term trajectory across 47 quarterly and live scoring snapshots.

✦

Fun facts about Valneva SE

Quirks, history, and lore behind VALN — the kind of stuff that makes a stock memorable.

1
The Basics
A European biotech company · small-cap · listed on Nasdaq · headquartered in France with major operations in Austria and Scotland.
2
The Numbers
Revenue in the tens of millions of euros, with the company still largely in investment and development mode — profits are not yet the point.
3
The History
Founded around 1999, it spent two decades quietly building a pipeline focused on infectious disease vaccines for which there are few or no existing approved options.
4
The Secret
Its biggest near-win came when a COVID-19 vaccine partnership with the UK government collapsed in 2022 — a very public stumble that hammered its stock.
5
The Lore
It won approval for the world's first and only chikungunya vaccine — a disease most people can't pronounce, let alone knew needed a vaccine.
6
The Giveaway
This Franco-Austrian vaccine specialist also holds an approved travel vaccine against Japanese encephalitis and trades on Nasdaq under a ticker that matches its name almost letter for letter.

▶ Think you know your stocks? Play the Daily Ticker

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+3.0% YoY

$174.7MFY 2025

FY22 $361.3MFY23 $153.7MFY24 $169.6MFY25 $174.7M

Total Assets

-20.2% YoY

$398.8MFY 2025

FY22 $621.3MFY23 $460.1MFY24 $500.0MFY25 $398.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$174.7M +3.0%	$169.6M +10.3%	$153.7M -57.5%	$361.3M +3.8%	$348.1M +215.5%	$110.3M
Total Assets	$398.8M -20.2%	$500.0M +8.7%	$460.1M -26.0%	$621.3M -24.0%	$817.4M +82.0%	$449.2M

Get alerted when VALN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Valneva SE including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VALN

Frazier Life Sciences Management, L.P.
$12.0M2,291,666 sh
Vivo Capital, LLC
$4.0M763,199 sh
GENERAL AMERICAN INVESTORS CO INC
$1.9M354,361 sh
MILLENNIUM MANAGEMENT LLC
$707.2K135,223 sh
WELLS FARGO & COMPANY/MN
$403.8K77,214 sh
MORGAN STANLEY
$294.0K56,217 sh
IRONWOOD INVESTMENT MANAGEMENT LLC
$235.7K45,064 sh
CITADEL ADVISORS LLC
$106.1K20,294 sh
XTX Topco Ltd
$79.4K15,178 sh
VSM Wealth Advisory, LLC
$52.3K10,000 sh

Fund	Value	Shares
Frazier Life Sciences Management, L.P.	$12.0M	2,291,666
Vivo Capital, LLC	$4.0M	763,199
GENERAL AMERICAN INVESTORS CO INC	$1.9M	354,361
MILLENNIUM MANAGEMENT LLC	$707.2K	135,223
WELLS FARGO & COMPANY/MN	$403.8K	77,214
MORGAN STANLEY	$294.0K	56,217
IRONWOOD INVESTMENT MANAGEMENT LLC	$235.7K	45,064
CITADEL ADVISORS LLC	$106.1K	20,294
XTX Topco Ltd	$79.4K	15,178
VSM Wealth Advisory, LLC	$52.3K	10,000

Companies Similar to VALN

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

SVA

SINOVAC BIOTECH LTD

AI score

Very similar · 1 shared holders

Vivo Capital, LLC

TIL

Instil Bio, Inc.

AI score

Shared smart-money ownership · 1 shared holders

Vivo Capital, LLC

TRIB

TRINITY BIOTECH PLC

AI score

Similar quality profile

CLLS

Cellectis S.A.

AI score

Similar quality profile

ASND

Ascendis Pharma A/S

AI score

Similar quality profile · 1 shared holders

Frazier Life Sciences Management, L.P.

IMMP

IMMUTEP Ltd

AI score

Similar quality profile

SERA

SERA PROGNOSTICS, INC.

AI score

Similar quality profile · 1 shared holders

Vivo Capital, LLC

NBTX

Nanobiotix S.A.

AI score

Similar quality profile

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VALN on your watchlist

Track score changes the day Valneva SE files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VALN a good stock to buy?

13F Pro's AI-powered analysis of Valneva SE (VALN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VALN are available on the VALN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VALN is classified as a small company.

Which hedge funds own VALN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VALN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Valneva SE's investment landscape.